Zuhair K Ballas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/272189/publications.pdf

Version: 2024-02-01

57758 46799 8,341 132 44 89 citations h-index g-index papers 193 193 193 9797 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Data Resource Profile: Self-reported data in the Million Veteran Program: survey development and insights from the first 850â€S736 participants. International Journal of Epidemiology, 2023, 52, e1-e17.	1.9	7
2	AUTOIMMUNE RETINOPATHY MIMICKING HERITABLE RETINAL DEGENERATION IN A PATIENT WITH COMMON VARIABLE IMMUNE DEFICIENCY. Retinal Cases and Brief Reports, 2022, 16, 111-117.	0.6	4
3	Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data from the USIDNET Registry. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	O
4	The 2022 AAAAI Foundation Faculty Development awardees. Journal of Allergy and Clinical Immunology, 2022, 149, 1574-1578.	2.9	1
5	2020: The year in review. Journal of Allergy and Clinical Immunology, 2021, 147, 495-497.	2.9	0
6	Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. Journal of Infectious Diseases, 2021, 224, 1372-1382.	4.0	10
7	The 2021 AAAAI Foundation Faculty Development awardees. Journal of Allergy and Clinical Immunology, 2021, 147, 1629-1633.	2.9	2
8	Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. Cancers, 2021, 13, 3676.	3.7	13
9	Increased mortality associated with frequent exacerbations in COPD patients with mild-to-moderate lung function impairment, and smokers with normal spirometry. Respiratory Medicine: X, 2021, 3, 100025.	1.4	3
10	Evaluation of staging criteria for disposition and airway intervention in emergency department angioedema patients. Acute Medicine & Surgery, 2021, 8, e704.	1.2	4
11	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2020, 145, 81-84.	2.9	0
12	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. EJHaem, 2020, 1, 537-544.	1.0	2
13	Characterization of serum biomarkers during anaphylaxis in emergency department patients. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3213-3215.e1.	3.8	5
14	AAAAI Foundation Faculty Development awardees: 2020. Journal of Allergy and Clinical Immunology, 2020, 145, 1148-1152.	2.9	4
15	Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. Critical Care Medicine, 2020, 48, 623-633.	0.9	188
16	2019: The year in review. Journal of Allergy and Clinical Immunology, 2020, 145, 788-790.	2.9	0
17	Preliminary findings from a concise emergency department model to predict anaphylaxis and develop a clinical decision support tool. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2479-2480.e1.	3.8	1
18	Gender Differences in Demographic and Health Characteristics of the Million Veteran Program Cohort. Women's Health Issues, 2019, 29, S56-S66.	2.0	41

#	Article	IF	CITATIONS
19	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2019, 144, 393-394.	2.9	O
20	Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. American Journal of Human Genetics, 2019, 105, 763-772.	6.2	169
21	The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Critical Reviews in Oncology/Hematology, 2019, 143, 148-152.	4.4	60
22	The Journal of Allergy and Clinical Immunology: 90 years strong. Journal of Allergy and Clinical Immunology, 2019, 144, 1161-1162.	2.9	1
23	The 2019 AAAAI Foundation Faculty Development awardees. Journal of Allergy and Clinical Immunology, 2019, 143, 2019-2023.	2.9	2
24	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2019, 144, 1154-1155.	2.9	0
25	The Editors' Choice. Journal of Allergy and Clinical Immunology, 2019, 144, 1509-1510.	2.9	0
26	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society, 2019, 16, 22-28.	3.2	458
27	Controversies in Drug Allergy: Consensus Documents From the World Experts. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 66-67.	3.8	1
28	Controversies in drug allergy: Consensus documents from the world experts. Journal of Allergy and Clinical Immunology, 2019, 143, 82-83.	2.9	2
29	Alcohol Consumption and Risk of Coronary Artery Disease (from the Million Veteran Program). American Journal of Cardiology, 2018, 121, 1162-1168.	1.6	23
30	DASH Score and Subsequent Risk of Coronary Artery Disease: The Findings From Million Veteran Program. Journal of the American Heart Association, 2018, 7, .	3.7	32
31	Adverse Events Associated with Immune Checkpoint Blockade. New England Journal of Medicine, 2018, 378, 1163-1165.	27.0	79
32	Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. Journal of Allergy and Clinical Immunology, 2018, 141, 1028-1035.	2.9	172
33	Controversies in drug allergy: consensus documents from the world experts. World Allergy Organization Journal, 2018, 11, 41.	3.5	1
34	The 2018 Nobel Prize in Physiology or Medicine: An exemplar of bench to bedside in immunology. Journal of Allergy and Clinical Immunology, 2018, 142, 1752-1753.	2.9	24
35	The 2018 American Academy of Allergy, Asthma & Development awardees. Journal of Allergy and Clinical Immunology, 2018, 142, 67-70.	2.9	0
36	Asthma clinical practice guidelines: Time for an update. Journal of Allergy and Clinical Immunology, 2018, 142, 787.	2.9	4

3

#	Article	IF	Citations
37	Biologic response modifiers: Indications, implications, and insights. Journal of Allergy and Clinical Immunology, 2017, 139, 1445-1456.	2.9	25
38	Gastrointestinal Manifestations in X-linked Agammaglobulinemia. Journal of Clinical Immunology, 2017, 37, 287-294.	3.8	51
39	Significance of Hyperferritinemia in Hospitalized Adults. American Journal of the Medical Sciences, 2017, 354, 152-158.	1.1	16
40	The future of allergy/immunology: Promising young investigators. Journal of Allergy and Clinical Immunology, 2017, 140, 384-386.	2.9	2
41	A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults. Journal of Clinical Immunology, 2017, 37, 638-643.	3.8	54
42	Recurrent Mycobacterium avium Complex Infection. Infectious Diseases in Clinical Practice, 2017, 25, e6-e8.	0.3	0
43	The Journal of Allergy and Clinical Immunology : An update on style and substance. Journal of Allergy and Clinical Immunology, 2017, 140, 60-62.	2.9	0
44	Immunoglobulin replacement therapy reduces chronic rhinosinusitis in patients with antibody deficiency. International Forum of Allergy and Rhinology, 2017, 7, 30-36.	2.8	17
45	Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE, 2017, 12, e0172437.	2.5	45
46	Precision medicine and precision health: Building blocks to foster a revolutionary health care model. Journal of Allergy and Clinical Immunology, 2016, 137, 1359-1361.	2.9	26
47	Nicotine Mediates CD161a ⁺ Renal Macrophage Infiltration and Premature Hypertension in the Spontaneously Hypertensive Rat. Circulation Research, 2016, 119, 1101-1115.	4.5	39
48	A new beginning: Building on the past, looking to the future. Journal of Allergy and Clinical Immunology, 2016, 137, 46-47.	2.9	2
49	Hypogammaglobulinemia with normal antibody response progressing to common variable immunodeficiency. Annals of Allergy, Asthma and Immunology, 2015, 114, 522-523.	1.0	1
50	Novel Role for Endogenous Hepatocyte Growth Factor in the Pathogenesis of Intracranial Aneurysms. Hypertension, 2015, 65, 587-593.	2.7	22
51	Combined immunodeficiency in the United States and Kuwait: Comparison of patients' characteristics and molecular diagnosis. Clinical Immunology, 2015, 161, 170-173.	3.2	22
52	Practice parameter for the diagnosis and management of primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2015, 136, 1186-1205.e78.	2.9	564
53	Cholinergic Stimulation with Nicotine Induces CD68+ Macrophage Infiltration into Kidney and Increases Arterial Pressure in Spontaneously Hypertensive Rats. FASEB Journal, 2015, 29, 957.7.	0.5	0
54	Recommendations for live viral and bacterial vaccines inÂimmunodeficient patients and their close contacts. Journal of Allergy and Clinical Immunology, 2014, 133, 961-966.	2.9	128

#	Article	IF	CITATIONS
55	Localized Increase of Chemokines in the Lumen of Human Cerebral Aneurysms. Stroke, 2013, 44, 2594-2597.	2.0	63
56	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ⁹⁰ yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed Bâ€cell nonâ€Hodgkin lymphoma. American Journal of Hematology, 2013, 88, 589-593.	4.1	33
57	The Glycophosphatidylinositol Anchor of the MCMV Evasin, m157, Facilitates Optimal Cell Surface Expression and Ly49 Receptor Recognition. PLoS ONE, 2013, 8, e67295.	2.5	1
58	Role of NK Cell Subsets in Organ-Specific Murine Melanoma Metastasis. PLoS ONE, 2013, 8, e65599.	2.5	33
59	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 211-217.	1.3	82
60	Neurohormonal Modulation of the Innate Immune System Is Proinflammatory in the Prehypertensive Spontaneously Hypertensive Rat, a Genetic Model of Essential Hypertension. Circulation Research, 2012, 111, 1190-1197.	4.5	97
61	Immune response modifiers in the treatment of asthma: AÂPRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2012, 130, 311-324.	2.9	18
62	Future of Allergy/Immunology Task Force Report. Journal of Allergy and Clinical Immunology, 2012, 130, 1009-1010.	2.9	8
63	Use and interpretation of diagnostic vaccination in primary immunodeficiency: AÂworking group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Dimmunology, Journal of Allergy and Clinical Immunology, 2012, 130, S1-S24.	2.9	379
64	A Dynamic Flux in Natural Killer Cell Subsets as a Function of the Duration of Alcohol Ingestion. Alcoholism: Clinical and Experimental Research, 2012, 36, 826-834.	2.4	19
65	High Prevalence of Humoral Immunodeficiency Patients with Refractory Chronic Rhinosinusitis. American Journal of Rhinology and Allergy, 2010, 24, 409-412.	2.0	49
66	Glycosylation contributes to variability in expression of murine cytomegalovirus m157 and enhances stability of interaction with the NKâ€cell receptor Ly49H. European Journal of Immunology, 2010, 40, 2618-2631.	2.9	8
67	Antibody response to pneumococcal vaccination as a function of preimmunization titer. Journal of Allergy and Clinical Immunology, 2009, 123, 195-200.	2.9	63
68	Idiopathic systemic capillary leak syndrome: Novel therapy for acute attacks. Journal of Allergy and Clinical Immunology, 2009, 124, 1111-1113.	2.9	68
69	Adverse reactions to vaccines. Annals of Allergy, Asthma and Immunology, 2009, 103, S1-S14.	1.0	48
70	HYPEREOSINOPHILIA: A CASE WITH AN ELUSIVE ETIOLOGY. Annals of Allergy, Asthma and Immunology, 2009, 103, 176-177.	1.0	0
71	EOSINOPHILIC FASCIITIS MASQUERADING AS ANGIOEDEMA. Annals of Allergy, Asthma and Immunology, 2009, 102, 258-259.	1.0	2
72	A Novel Therapy for Lymphedema. Archives of Internal Medicine, 2009, 169, 201.	3.8	2

#	Article	IF	Citations
73	Assessment of Natural Killer (NK) and NKT Cells in Murine Spleens and Livers. Methods in Molecular Biology, 2008, 447, 259-276.	0.9	11
74	Immunomodulators: A brave new world. Journal of Allergy and Clinical Immunology, 2008, 121, 331-333.	2.9	8
7 5	The Reply:. American Journal of Medicine, 2008, 121, e15.	1.5	0
76	REVERSIBLE PANHYPOGAMMAGLOBULINEMIA ASSOCIATED WITH THE ANTIEPILEPTIC AGENT LEVETIRACETAM. Annals of Allergy, Asthma and Immunology, 2008, 101, 108-109.	1.0	13
77	Assessing siRNA Pharmacodynamics in a Luciferase-expressing Mouse. Molecular Therapy, 2008, 16, 1995-2001.	8.2	21
78	Evaluation of the Adult with Suspected Immunodeficiency. American Journal of Medicine, 2007, 120, 764-768.	1.5	32
79	Effectiveness of delayed epinephrine in anaphylaxis. Journal of Allergy and Clinical Immunology, 2007, 120, 716-717.	2.9	6
80	Thymocytes, Preâ€B Cells, and Organ Changes in a Mouse Model of Chronic Ethanol Ingestion—Absence of Subsetâ€Specific Glucocorticoidâ€Induced Immune Cell Loss. Alcoholism: Clinical and Experimental Research, 2007, 31, 1746-1758.	2.4	72
81	Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunologic Research, 2007, 39, 15-21.	2.9	28
82	Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology, 2006, 117, 134-140.	2.9	329
83	Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN- $\hat{l}\pm$. Journal of Allergy and Clinical Immunology, 2006, 118 , 526 - 528 .	2.9	11
84	Natural killer cells in human health and disease. Clinical Immunology, 2006, 118, 1-10.	3.2	280
85	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. Journal of Immunotherapy, 2006, 29, 558-568.	2.4	145
86	Association of immune abnormalities with telomere shortening in autosomal-dominant dyskeratosis congenita. Blood, 2005, 105, 682-688.	1.4	73
87	Rapid intravenous cephalosporin desensitization. Journal of Allergy and Clinical Immunology, 2005, 116, 225-228.	2.9	20
88	Perilesional GM-CSF therapy of a chronic leg ulcer in a patient with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2005, 116, 460-462.	2.9	3
89	Caseating granulomatous disease in common variable immunodeficiency treated with infliximab. Journal of Allergy and Clinical Immunology, 2005, 116, 1161-1162.	2.9	63
90	Practice parameter for the diagnosis and management of primary immunodeficiency. Annals of Allergy, Asthma and Immunology, 2005, 94, S1-S63.	1.0	452

#	Article	IF	Citations
91	Chronic ethanol ingestion by mice increases expression of CD80 and CD86 by activated macrophages. Alcohol, 2004, 32, 91-100.	1.7	28
92	T-cell activation after chronic ethanol ingestion in mice. Alcohol, 2004, 33, 175-181.	1.7	50
93	The presentation and natural history of immunodeficiency caused by nuclear factor ΰB essential modulator mutation. Journal of Allergy and Clinical Immunology, 2004, 113, 725-733.	2.9	174
94	Acute thromboembolic events associated with intravenous immunoglobulin infusion in antibody-deficient patients. Journal of Allergy and Clinical Immunology, 2003, 112, 797-799.	2.9	28
95	Structural Characterization of the Inhibitory DNA Motif for the Type A (D)-CpG–Induced Cytokine Secretion and NK-Cell Lytic Activity in Mouse Spleen Cells. DNA and Cell Biology, 2003, 22, 621-631.	1.9	55
96	Natural killer cells: emerging concepts in immunity to infection and implications for assessment of immunodeficiency. Current Opinion in Pediatrics, 2003, 15, 586-593.	2.0	12
97	Highly Immunostimulatory CpG-Free Oligodeoxynucleotides for Activation of Human Leukocytes. Oligonucleotides, 2002, 12, 165-175.	4.3	59
98	Aberrant T-Cell Antigen Receptor-Mediated Responses in Autoimmune Lymphoproliferative Syndrome. Clinical Immunology, 2002, 104, 31-39.	3.2	15
99	Deficient NK-cell function in adult patients with recurrent non-invasive mucosal candidiasis. Journal of Allergy and Clinical Immunology, 2002, 109, S186-S186.	2.9	2
100	Deficient natural killer cell cytotoxicity in patients with IKK- $\hat{I}^3/NEMO$ mutations. Journal of Clinical Investigation, 2002, 109, 1501-1509.	8.2	160
101	Deficient natural killer cell cytotoxicity in patients with IKK- $\hat{I}^3/NEMO$ mutations. Journal of Clinical Investigation, 2002, 109, 1501-1509.	8.2	94
102	Chronic ethanol consumption by mice results in activated splenic T cells. Journal of Leukocyte Biology, 2002, 72, 1109-16.	3.3	92
103	TH1 cytokine response of CD57+ T-cell subsets in healthy controls and patients with alcoholic liver disease. Alcohol, 2001, 24, 155-167.	1.7	42
104	Identification of CpG oligonucleotide sequences with high induction of IFN- $\hat{l}\pm\hat{l}^2$ in plasmacytoid dendritic cells. European Journal of Immunology, 2001, 31, 2154-2163.	2.9	790
105	Immune Dysfunction in Refractory Sinusitis in a Tertiary Care Setting. Laryngoscope, 2001, 111, 233-235.	2.0	117
106	Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs. Journal of Immunology, 2001, 167, 4878-4886.	0.8	221
107	CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. International Immunology, 2001, 13, 1013-1020.	4.0	37
108	Identification of CpG oligonucleotide sequences with high induction of IFN- $\hat{l}\pm\hat{l}^2$ in plasmacytoid dendritic cells. , 2001, 31, 2154.		3

#	Article	IF	Citations
109	Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo. Journal of Immunology, 2000, 164, 1617-1624.	0.8	550
110	NK cytokine secretion and cytotoxicity occur independently of the SLP-76 adaptor protein. European Journal of Immunology, 1999, 29, 2223-2232.	2.9	45
111	CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthmaâ~†â~†â~†â~tâ Journal of Allergy and Clinical Immunology, 1999, 104, 1258-1264.	2.9	132
112	Preoperative steroids confuse the diagnosis of allergic fungal sinusitis. Journal of Allergy and Clinical Immunology, 1998, 101, 139-140.	2.9	18
113	Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma. Blood, 1997, 89, 2994-2998.	1.4	184
114	Ethanol and Natural Killer Cells. I. Activity and Immunophenotype in Alcoholic Humans. Alcoholism: Clinical and Experimental Research, 1997, 21, 974-980.	2.4	54
115	Ethanol and Natural Killer Cells. II. Stimulation of Human Natural Killer Activity by Ethanol In Vitro. Alcoholism: Clinical and Experimental Research, 1997, 21, 981-987.	2.4	15
116	Modulation of T-Cell Adhesion Markers, and the CD45R and CD57 Antigens in Human Alcoholics. Alcoholism: Clinical and Experimental Research, 1995, 19, 555-563.	2.4	68
117	Fine T-Cell Subsets in Alcoholics as Determined by the Expression of l-Selectin, Leukocyte Common Antigen, and beta-Integrin. Alcoholism: Clinical and Experimental Research, 1994, 18, 71-80.	2.4	49
118	Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Survey of Ophthalmology, 1993, 38, 141-148.	4.0	97
119	Substance P does not alter interleukin-1 expression by splenic or granuloma macrophages in murine schistosomiasis. Journal of Neuroimmunology, 1991, 33, 217-225.	2.3	6
120	Lymphokine-activated killer (LAK) cells. Cellular Immunology, 1991, 134, 296-313.	3.0	22
121	Murine natural killer cells express the Ly24 (Pgp-1) marker on their surface. Cellular Immunology, 1990, 125, 449-458.	3.0	5
122	A patient with simultaneous absence of "classical―natural killer cells (CD3â^', CD16+, and NKH1+) and expansion of CD3+, CD4â^', CD8â^', NKH1+ subset. Journal of Allergy and Clinical Immunology, 1990, 85, 453-459.	2.9	65
123	Inhibition of lymphocyte activation with anti-transferrin receptor Mabs: A comparison of three reagents and further studies of their range of effects and mechanism of action. Cellular Immunology, 1989, 122, 218-230.	3.0	22
124	Natural Killer Cell Activity in Major Depression. , 1987, , 369-372.		1
125	Alteration of human accessory cell function by heat treatment: Role of IL-1 and class II MHC antigens. Human Immunology, 1986, 16, 234-246.	2.4	8
126	Interleukin 2 induces interferon $\hat{l}\pm\hat{l}^2$ production in mouse bone marrow cells. Cellular Immunology, 1986, 102, 374-385.	3.0	10

ZUHAIR K BALLAS

#	Article	IF	CITATIONS
127	Cryopreservation of CTLL, a murine IL2-dependent cell line. Trends in Immunology, 1985, 6, 145.	7.5	0
128	Generation of cytotoxic T lymphocytes against modified self in the absence of antigen by interleukin 2-containing preparations. Cellular Immunology, 1983, 76, 81-93.	3.0	18
129	Complement inhibits immune responses: C3 preparations inhibit the generation of human cytotoxic T lymphocytes. European Journal of Immunology, 1983, 13, 279-284.	2.9	14
130	Sulindac-Induced Aseptic Meningitis. Archives of Internal Medicine, 1982, 142, 165.	3.8	61
131	Complement fragments suppress lymphocyte immune responses. Trends in Immunology, 1982, 3, 238-243.	7.5	42
132	Studies on the mechanism of T-cell-mediated lysis. Cellular Immunology, 1981, 59, 411-418.	3.0	5